The two novel MAO-B inhibitors, Cmp3 and Cmp5, appeared as promising molecules targeting MAO-B and reporting in glioma cells a percentage of cell viability notably lower than that recorded for TMZ, which is the most used drug in GBM. The gene discussed is MAOB; the disease is glioma.